Certara Partners with Critical Path Institute to Develop Population-Based Lung Model to Test New Tuberculosis Drugs


Company News Release

Computer simulation will be able to mimic drug disposition in the lungs at different stages of tuberculosis infection


™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that it is partnering with the

Critical Path Institute

(“C-Path”) to develop a physiologically-based pharmacokinetic (PBPK) model of the human lung. Built to work in conjunction with Certara’s Simcyp™ Population-based Simulator, the model will be used to predict the disposition of drugs within the lungs and the potential impact of disease-progression on drug kinetics at different stages of tuberculosis (TB) infection.

TB is a debilitating disease that can prove deadly. There were an estimated 8.7 million new cases of TB in 2011 and 1.4 million people died of the disease during that year, according to the World Health Organization.

“This model can be used by drug developers to define dose regimens that will produce clinical concentrations of anti-TB drugs at target sites in the lungs, and help to expedite the development of new TB treatments,” said C-Path President and CEO Dr. Martha Brumfield. “The majority of drugs that are currently used to treat TB are more than 40 years old, have significant side effects and drug interactions, and require a long treatment period. Furthermore, they are becoming less effective as TB strains are growing increasingly drug resistant,” she explained.

“This lung simulation tool will allow pharmaceutical companies to simulate a wide range of variables in terms of drug dose, disease state, and concomitant medications for a much more efficient clinical trial design process,” said Daniel Weiner, Ph.D., senior vice president and general manager at Certara. “Our Simcyp Simulator can already model population variability in PK, pharmacodynamic and cardiotoxicity responses. We are now building models to study different aspects of drug activity in the liver, heart and lungs.”

This TB project will result in another tool to help drug development similar to the Alzheimer’s disease (AD) clinical trial simulation platform from C-Path’s Coalition Against Major Diseases. That tool, which uses a computer model to simulate “what if” clinical trial scenarios, was the first of its kind to receive a regulatory decision as “fit-for-purpose” from the U.S. Food and Drug Administration, and formal qualification from the European Medicines Agency, in July 2013. It is now available as a resource for sponsors developing AD drugs.

Development of the lung model is being supported by the Critical Path to TB Drug Regimens (CPTR) Initiative, which is a collaboration of pharmaceutical companies; government, regulatory, and multilateral agencies; academia; civil society; advocates; and non-government organizations, which aims to accelerate the development of new, safe, and highly effective TB treatment regimens with shorter therapy durations.

C-Path will be exploring further the benefits of using population-based simulations to enhance the drug development process during its “Modeling and Simulation for Medical Product Development and Evaluation Workshop,” which will be held on Sept. 26 at the W Hotel in Washington, DC. Additional information about the workshop, including registration details, can be found



Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.